FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1204-1206 October 14, 1993 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited

To the Editor: In describing the results of a placebo-controlled study of captopril in patients with left ventricular dysfunction after myocardial infarction, Pfeffer et al. (Sept. 3, 1992, issue)¹ reported that significantly fewer patients given captopril had at least one recurrent infarction (170 patients in the placebo group and 133 in the captopril group). This result is not as clear-cut as the report suggests. The favorable finding arose from a post hoc reanalysis of the data.

The protocol of the Survival and Ventricular Enlargement (SAVE) trial precisely defined the criteria for recurrent myocardial infarction: 1) new Q or QS waves . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Kober, L., Torp-Pedersen, C., Carlsen, J. E., Bagger, H., Eliasen, P., Lyngborg, K., Videbak, J., Cole, D. S., Auclert, L., Pauly, N. C., Aliot, E., Persson, S., Camm, A. J., The Trandolapril Cardiac Evaluation (TRACE) study, (1995). A Clinical Trial of the Angiotensin-Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction after Myocardial Infarction. NEJM 333: 1670-1676 [Abstract] [Full Text]